MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--June 19, 2006--ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today the presentation of new clinical data supporting the use of Ceflatonin® (homoharringtonine or HHT) as a treatment for chronic myeloid leukemia (CML) patients who have developed resistance to Gleevec® or other tyrosine kinase inhibitors. The data, presented at the European Hematology Association meeting held this week in Amsterdam, looked retrospectively at 15 patients with chronic or accelerated phase CML who had received HHT as salvage therapy in order to achieve a complete hematologic response following treatment failure of either imatinib mesylate (Gleevec®), the currently approved first-line therapy, or interferon.
